"versionIdentifier","rationale","uuid:ID","instanceType","id"
"2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","7341b047-ccd6-4ed3-8205-f598e163f726","StudyVersion","StudyVersion_1"
